Pay in 4 interest-free payments of $6.99 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Bhattarai M, Salih M, Regmi M, et al
Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures
The Peptide Catalog is not responsible for medical decisions made based on information presented here
If you still want to explore peptides, do it with a licensed clinician, introduce one compound at a time, and verify your source
While these side effects are typically dose-related and often fade over time, they remain the leading reason for early drop-out from clinical trials
It contains the active ingredient semaglutide, which can cause side effects such as gastrointestinal disruption
